Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout
Gilead Sciences is set to acquire Ouro Medicines for $2.2bn, marking the company’s first move into the T-cell engager (TCE)…
24 Mar 2026
Monash University and ClinChoice partner on new therapies development
Australia-based Monash University and ClinChoice have announced a strategic partnership to accelerate clinical development of new therapies. This collaboration is also aimed at expediting early-phase clinical trials and delivering new…
24 Mar 2026
Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody
Sanofi has signed an exclusive global licence agreement with Kali Therapeutics for KT501, a new tri-specific antibody for B cell-mediated autoimmune diseases. The agreement grants Sanofi worldwide rights to KT501,…
23 Mar 2026
Earendil Labs lands $787m to fund biologics development push
Earendil Labs has secured $787m to drive the expansion of its artificial intelligence (AI)-powered drug discovery platform, which has already garnered interest from big pharma player, Sanofi. Investment has come…
23 Mar 2026
ImmunityBio receives Macau approval for Anktiva combo therapy
ImmunityBio has received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China, for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for bladder…
23 Mar 2026
BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma
Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has received approvals for two new indications in classical Hodgkin Lymphoma (cHL) from the US Food and Drug Administration (FDA) and the European Commission…
20 Mar 2026
Novo Nordisk’s Wegovy HD secures FDA greenlight amid patent expiries
Novo Nordisk has landed an approval from the US Food and Drug Administration (FDA) for a high dose version of its best-selling weight loss drug, Wegovy (semaglutide), as patents covering…